Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Ted William Johnson"'
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Aaron N. Hata, Jennifer L Peterson, Scott L. Weinrich, Satoshi Yoda, Jessica J. Lin, Adam Acker, Aya Shiba-Ishii, Ibiayi Dagogo-Jack, Lesli A. Kiedrowski, Justin F. Gainor, Kristin Dionne, Michele McTigue, Andrew Do, Makeba A Walcott, Mari Mino-Kenudson, Jaimie L. Barth, Ted William Johnson, Beow Y. Yeap, Ping Wei, Linh Nguyen-Phuong, Theodore R. Johnson
The treatment approach to advanced, ALK-positive non-small cell lung cancer (NSCLC) utilizing sequential ALK tyrosine kinase inhibitors (TKIs) represents a paradigm of precision oncology. Lorlatinib is currently the most advanced, potent and selectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0a276b417464b334652691d18f8ae4c0
https://doi.org/10.1101/2021.07.16.452681
https://doi.org/10.1101/2021.07.16.452681
Autor:
Romelia Salomon-Ferrer, Lawrence G. Lum, Todd VanArsdale, Nathan V. Lee, Andrew C. Wang, Aihua Zou, Koleen Eisele, Eric C. Greenwald, Catherine M. Ambler, Ana Flores-Bojorquez, Bryan Li, Carl Davis, Sergei Timofeevski, Martha A. Ornelas, Zhenxiong Wang, Penney L. Khamphavong, Samantha Elizabeth Greasley, Indrawan James Mcalpine, Michael F. Maestre, Jian Li, Ben Bolaños, Neil B. Grodsky, Yun Huang, Stephanie Scales, Ted William Johnson, Roksolana Melnychuk, Wade Diehl, Jon Oyer, Jacob DeForest, Sherry Niessen
Publikováno v:
Cancer Research. 81:330-330
Nomination of new oncology targets has been greatly aided by advances in genetic screening and profiling, but developing potent, selective small molecule inhibitors against these targets remains a resource intensive pursuit. To significantly de-risk
Autor:
Sergei Timofeevski, Sansana Sawasdikosol, Timothy Scott Fisher, Steven J. Burakoff, Robert Steven Kania, Ted William Johnson, Gallego Rebecca Anne, Ciarán N. Cronin, Eric Johnson, Michele McTigue, Michael F. Maestre
Publikováno v:
J Biol Chem
Hematopoietic progenitor kinase 1 (HPK1 or MAP4K1) is a Ser/Thr kinase that operates via the c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) signaling pathways to dampen the T-cell response and antitumor immunity. Accord
Autor:
Michael R. Collins, Paul F. Richardson, Neal W. Sach, Ted William Johnson, Jeff Elleraas, Jason Ewanicki
Publikováno v:
Angewandte Chemie. 128:3654-3659
Lorlatinib (PF-06463922) is an ALK/ROS1 inhibitor and is in clinical trials for the treatment of ALK positive or ROS1 positive NSCLC (i.e. specific subsets of NSCLC). One of the laboratory objectives for this molecule indicated that it would be desir
Autor:
Dan Gehlhaar, Alexei Brooun, Mehran Jalaie, Michele McTigue, Sergei Timofeevski, Ben Bolaños, Gallego Rebecca Anne, Ted William Johnson
Publikováno v:
ACS medicinal chemistry letters. 9(9)
[Image: see text] Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that can become oncogenic by activating mutations or overexpression. Full kinetic characterization of both phosphorylated and nonphosphorylated wildtype and mutant ALK k
[Image: see text] Structure-based drug design (SBDD) is commonly leveraged in rational drug design. Usually, ligand and binding site atomic coordinates from crystallographic data are exploited to optimize potency and selectivity. In addition to tradi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::433858d7f4acc4552a7679cee53ca01a
https://europepmc.org/articles/PMC6142050/
https://europepmc.org/articles/PMC6142050/
Publikováno v:
Journal of medicinal chemistry. 61(15)
Lipophilic efficiency (LipE) is an important metric that has been increasingly applied in drug discovery medicinal chemistry lead optimization programs. In this Perspective, using literature drug discovery examples, we discuss the concept of rigorous
Autor:
Alice T. Shaw, Luc Friboulet, Daria Timonina, Benjamin J. Burke, Krystina E. Kattermann, Justin F. Gainor, Jeffrey A. Engelman, Amanda K. Riley, A. John Iafrate, Jochen K. Lennerz, Adam Langenbucher, Sergei Timofeevski, Aaron N. Hata, Leila Dardaei, Cyril H. Benes, Lorin A. Ferris, Jessica J. Lin, Kylie Prutisto-Chang, Ted William Johnson, Harper Hubbeling, Rebecca S. Heist, Ibiayi Dagogo-Jack, Mari Mino-Kenudson, Satoshi Yoda, Michael S. Lawrence
Publikováno v:
Cancer Discovery
The cornerstone of treatment for advanced ALK-positive lung cancer is sequential therapy with increasingly potent and selective ALK inhibitors. The third-generation ALK inhibitor lorlatinib has demonstrated clinical activity in patients who failed pr
Protein kinases are an important class of drug targets with approval of 40 drugs treating diseases in immunology, inflammation and oncology. Early enablement of parallel synthetic chemistry produced large numbers of compound sets for screening, many
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1687520d6c2444ed921b1a5fea49f86
https://doi.org/10.1039/9781788013093-00216
https://doi.org/10.1039/9781788013093-00216